BioDiscovery develops, markets and sells advanced software solutions for the analysis of data from high-throughput microarray and next-generation sequencing technologies.
BioDiscovery provides a full line of modular software packages spanning image analysis, microarray data processing, and advanced analysis of CNV and expression data built for power (handling of large scale data with ease), versatility (able to handle and process data from all commercial platforms), efficiency (optimum usage of computing resources) and offers an acute sense of fitness for purpose (usefulness to our community of users). These products empower Biologists and Geneticists with sophisticated, yet highly usable tools to analyze and interpret their data and draw meaningful conclusions.
BioDiscovery was founded in 1997, in Los Angeles, California as a pioneer in the then nascent field of microarray informatics. The company has since positioned itself as an innovative force in the industry with a strong intellectual property portfolio encompassing six issued U.S. patents and a significant number of pending applications. This dedicated focus has produced a number of first-to-market products and technologies including:
Innovations in Image Analysis:
- First fully automated image analysis product for microarrays.
- First company to apply advanced spot image segmentation, and novel image analysis algorithms to microarray images.
Innovations in Microarray Data Analysis:
- First commercial package for microarray data analysis.
- First array fabrication tracking and databasing tool.
- First company to promote the need for quality measures and incorporate improved quantitative accuracy as well as statistical confidence measurements to microarrays.
- First company to implement Self-Organizing Maps (SOM) in a commercial product for analysis of expression array data.
- First company to implement Principal Component Analysis (PCA) in a commercial product for analysis of expression array data.
Today, BioDiscovery counts over 3000 customers across over 30 countries. We believe that we are poised to make a difference in the world of genomic data analysis as the use of this technology further develops in drug discovery and diagnostics.